Reaction
Cutaneous Symptom reporting signals
As of the last recalculation, Cutaneous Symptom appears in 660 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is METHYLPREDNISOLONE ACETATE (PRR 44.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Methylprednisolone Acetate | 11 | 44.0 | 44.1 |
| Gefitinib | 11 | 39.1 | 39.1 |
| Peginterferon Beta-1A | 15 | 36.9 | 36.9 |
| Canakinumab | 9 | 26.6 | 26.6 |
| Cetuximab | 23 | 23.9 | 24.0 |
| Panitumumab | 10 | 20.4 | 20.4 |
| Encorafenib | 6 | 19.3 | 19.3 |
| Diroximel Fumarate | 5 | 13.3 | 13.3 |
| Obinutuzumab | 6 | 11.6 | 11.6 |
| Docetaxel Anhydrous | 23 | 11.1 | 11.1 |
| Docetaxel | 23 | 11.1 | 11.1 |
| Bosutinib | 3 | 10.6 | 10.6 |
| Avapritinib | 4 | 10.5 | 10.5 |
| Suvorexant | 4 | 9.8 | 9.8 |
| Osimertinib | 9 | 9.0 | 9.0 |
| Apalutamide | 3 | 8.1 | 8.1 |
| Apremilast | 22 | 4.9 | 4.9 |